Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367487 | 0.97 | ALDH1A1 (0.36) | ALDH1A1S1PR3MAPTL3MBTL1POLB | |
| SCHEMBL1366992 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MAPTL3MBTL1POLBAPLNR | |
| SCHEMBL1367091 | 0.84 | S1PR3 (0.43) | S1PR3 | |
| SCHEMBL1364339 | 0.81 | S1PR3 (0.41) | ALDH1A1S1PR3MAPTPOLB | |
| SCHEMBL1366943 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MAPTL3MBTL1POLB | |
| SCHEMBL2313628 | 0.79 | HTR2A (0.36) | ALDH1A1L3MBTL1POLB | |
| SCHEMBL1366513 | 0.77 | CYP2C9 (0.43) | CNR1CNR2 | |
| SCHEMBL1945423 | 0.75 | POLB (0.38) | ALDH1A1MAPTPOLBAPLNR | |
| SCHEMBL1366687 | 0.75 | CYP2C9 (0.46) | — | |
| SCHEMBL1943284 | 0.74 | POLB (0.38) | ALDH1A1MAPTPOLBAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNK3, KCNQ3, KCNN3 | ALDH1A1 2697/4885S1PR3 559/4885OPRK1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.